Levolta Pharmaceuticals is focused on overcoming significant challenges in the pharmaceutical industry by developing innovative therapies with an enhanced therapeutic index. Their approach includes a reformulation platform that aims to improve the probability of success in drug development while significantly reducing timelines through the use of 505(b)(2) regulatory filings. This strategy allows Levolta to expedite the development process by 8-10 years, addressing the lengthy and costly nature of traditional drug development. Their product pipeline features early-stage small molecules and late-stage novel combinations, including compounds like VOLT01, a derivative of Zoledronic Acid designed to enhance efficacy and reduce side effects, and VOLT02, which improves the solubility of progesterone for treating traumatic brain injury.

In addition to their reformulation efforts, Levolta is developing targeted therapies that focus on specific pathways in the immune response. They are working on Syk inhibitors, which aim to modulate immune cell activation and reduce inflammation, and small molecule compounds that inhibit Tumor Necrosis Factor (TNF), addressing the limitations of current biologic therapies. By leveraging their expertise in these areas, Levolta seeks to provide effective, safer, and more cost-efficient alternatives to existing treatments, ultimately driving value for both patients and the healthcare system.

United States

Levolta Pharmaceuticals is a biopharmaceutical company that offers a portfolio of early-stage small molecules and late-stage novel formulated compounds for various medical fields, including rheumatology, the central nervous system, oncology, and immunology.

Levolta Pharmaceuticals

Company Details